retatrutide mechanism of action triple agonist glp-1 gip glucagon Targeting GLP-1, & GCG in Obesity and Type 2 Diabetes Research Frontiers | Glucagon-like peptide-1 and

acknowledges the SOURCE program at Syracuse University for funding provided for A.M.G

We abstracted all relevant data reported in the included trials, including treatment discontinuation due to adverse events, all-cause death, cardiovascular disease, non-fatal stroke, kidney failure, severe hypoglycaemia, eye disease requiring intervention, health-related quality of life, serious gastrointestinal events, etc

Diab H, Fuquay T, Datta P, Bickel U, Thompson J, Krutsch K

Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis

doi: 10.1002/osp4.164 [DOI] [PMC free article] [PubMed] [Google Scholar] 40.NamKoong C, Kim MS, Jang BT, Lee YH, Cho YM, Choi HJ

Klinik Depresyon: Ktleme riskinde %44 azalma